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ABSTRACT 
The aim of pharmacogenetic studies is to adapt therapeutic strategies to individual genetic 
profiles, thus maximising their efficacy and minimising the likelihood of adverse side effects. 
Since the advent of personalised medicine, the issue of communicating research results to 
participants has become increasingly important. We addressed this question in the context of 
HIV infection, as patients and associations are particularly concerned by research and 
therapeutic advances. We explored the standpoints of both research professionals and 
participants involved in a pharmacogenetics study conducted in a cohort of HIV-infected 
patients. The setting of the research protocol was followed over a 2 years period. Participants’ 
standpoints were collected through a questionnaire and interviews were conducted with research 
professionals.Of 125 participants, 76% wished to receive individual results and 71% wished to 
receive collective results; 39% did not know when results might be expected. Communication of 
global research results is a principle that is generally accepted by professionals. Concerning 
individual feedback, the professionals felt that it was necessary if it could be of direct benefit to 
the participant, but they expressed doubts for situations with no recognised benefit.  
Our results highlight the necessity to consider this issue in greater detail. We suggest the need to 
anticipate the debates concerning individual feedback, to differentiate between situations and 
the importance of further investigations on the opportunities and modalities of communication. 
Finally, our work emphasised the opposite pressures between the pursuit of scientific 
knowledge and the therapeutic orientation of clinical trials. 
 
Keywords: clinical trials, pharmacogenetics, research participants, research result 
communication, HIV 
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INTRODUCTION 
 Pharmacogenetics studies the genetic factors that may influence the efficacy and toxicity of 
treatments. It is proving a promising way for HIV therapy and several genotype-phenotype 
associations for HIV have been determined 1-3. For example, Martin has established a genetic 
component for a clinically significant drug hypersensitivity to abacavir4. However, there are, at 
present, relatively few relevant associations and these need confirmation in larger populations. 
The medical impact and usefulness of pharmacogenetic testing in HIV are not clear due to the 
complexity of interfering factors such as gene/gene and gene/environment interactions. As 
research in pharmacogenetics develops, a number of ethical issues are raised5,6. Our study deals 
with the feedback of research results to participants. 
The question as to whether and how clinical research results should be communicated to 
participants is an emerging topic7-11, particularly in the domain of pharmacogenetics and HIV 
infection 1,12-15. Two levels of feedback are possible: global and individual. There is currently a 
consensus that the respect of research participants implies the communication of the global 
results to them at the end of the research. It has been suggested that it should be the role of 
research ethic committees (RECs) to ensure such feedback, after setting up the practical means 
and modalities 10. This standpoint was supported by the observation that only 30% of clinical 
research results are rendered public 16. It has also been argued that making public research 
results is a duty towards participants 17.  
 Communication of individual biological or clinical research data raises questions about 
their use in a nominative manner and about whether and how to respond to the demands of 
participants. Is this type of communication appropriate, given that it concerns research results 
that require further validation and the impacts of which for the patients are still uncertain? 
Appelbaum 18 showed that the separation between research and care is sometimes blurred. 
Indeed, patients may have difficulty distinguishing between the two types of activity as well as 
between experimental and validated data. All this raises questions concerning the nature of the 
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information to be given to the participant, the ways of managing and explaining the uncertainty 
inherent to research and lastly, the medical responsibility in play.  
These questions are particularly pertinent to pharmacogenetic studies concerning HIV-
infected patients. Indeed, because HIV infection is chronic and treatments are long and 
aggressive, HIV patients are naturally waiting for any scientific progress and information that 
could have an impact on their day-to-day lives with the disease. This explains why HIV 
patients’ associations actively follow clinical research protocols and are aware of the issues of 
information and communication to research participants. Our study was performed with HIV-
infected patients from the APROCO-COPILOTE cohort 12. Patients were asked to participate in 
a protocol designed to study the progression of the disease, response to treatment and the 
occurrence of adverse events as a function of genetic polymorphisms. The DNA Bank 
Monitoring Committee of the APROCO study (so called the “Monitoring Committee”) 
examined the opportunity to give global and/or individual results to research participants. In 
particular, the committee considered whether individual feedback would be of benefit to the 
patient and whether it would be pertinent for medical care. 
This article illustrates the practical approach adopted by the APROCO study group and 
describes the results of a study aiming to evaluate the points of view of healthcare  professionals 
and participants. The objective was to analyse criteria and procedures to be considered when 
communicating results to participants. 
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METHODS 
 
The APROCO-COPILOTE study is supported by the French National Agency for AIDS 
Research (ANRSEP11-EP22). The cohort includes 1281 HIV-infected patients who started 
taking a protease inhibitor-containing antiretroviral treatment between 1997 and 199919-22. A 
pharmacogenetic research protocol based on the use of DNA extracted from blood samples was 
initiated in January 2002 and samples were collected until June 2003. The protocol aimed to 
study genetic markers associated with disease progression as well as markers involved in the 
occurrence of treatment-associated adverse events23-26. Together with virological and clinical 
factors, genetic markers might affect patient health care by providing a better understanding of 
the factors influencing the response or tolerance to treatment. While setting up the project, the 
issues of information, consent and result feedback to participants were considered12.  
The issues were to identify and to analyse the arguments for and against the global and 
individual communication of research results and to examine how to take into account patients’ 
expectations. Four complementary methods were used:  
1- An external observer attended all meetings of the Monitoring Committee to record the 
arguments and points of view of the different actors concerned. This multidisciplinary 
committee12 consisted of the main investigators, ethics experts, a lawyer, a representative of the 
study promoter and a representative of patients' associations. Meetings were analysed for 
content concerning practical issues and relevance of the procedures laid down in the protocol for 
participant information and result feedback.  
2- The scientific professionals involved in the DNA bank project were interviewed to collect the 
viewpoints of three groups of professionals: 1) fundamental researchers, not involved in clinical 
care, 2) clinicians involved in the follow-up of patients and 3) the physicians in charge of co-
ordinating the project, involved directly or indirectly in care. They were asked to comment on 
the questions raised by individual and global research result feedback. 
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3- To analyse participants’ attitudes, the consent forms offered the possibility to express their 
wishes concerning research result feedback12. These forms were analysed in two large centres by 
a physician to respect confidentiality.  
4- The patients followed in 47 centres throughout France were asked to answer five multiple-
choice questions concerning: 1) their expectations in terms of global and/or individual results, 
2) the time at which they would expect to receive the results, 3) their interest in the information 
documents, 4) their expectations concerning personalised genetic information and 5) their 
reasons for participating in the research. The questionnaire, validated by the Monitoring 
Committee, was issued to patients during consultations with their physician and was returned 
anonymously. The results are expressed as frequencies of answers.
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RESULTS 
 
The professionals' points of view 
The Monitoring Committee 
The possible benefits accruing to HIV-infected patients participating in the protocol was 
the key issue that conditioned the views of healthcare professionals about the communication of 
results. This was discussed at all six committee meetings held over the 18-month study period 
and a clear distinction was made between global and individual result feedback. 
After stating the arguments in favour of a hypothetical benefit12, the professionals 
discussed the uncertainty of the impact of the results. It was pointed out that the impact of 
certain genetic markers on medical care was unclear and that it could not be ruled out that, for 
some patients, knowledge of their genetic profile could have unpredictable consequences on 
their experience of both illness and treatment. It was stressed that questions concerning result 
disclosure arise at three phases of the research:  
1) at the time of inclusion it concerns the information relating to result feedback. The 
professionals were particularly concerned by the consent form12;  
2) during the research it concerns the information about the selection of the genetic 
markers to be studied, taking into account scientific progress and potential medical impacts. The 
aim was to make the most pertinent choices, given the precious nature of the samples and their 
limited size. The investigators therefore sought to achieve a balance between scientific 
imperatives and a search for the greatest possible clinical benefits. To keep the participants 
informed of these choices, an information document for physicians was produced once per year 
including a sheet to be delivered to the participants during their follow-up visits. The aim of this 
document was to encourage physicians to provide oral information concerning overall results 
during follow-up visits. 
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 3) at the end of the research it concerns the decisions as to whether and how to provide 
global and/or individual feedback. The committee insisted that this debate took place well 
before the first results were obtained to define the best ways managing global and/or individual 
results communication 
The debate about the possibility of offering participants access to individual results 
remained open. Arguments in favour included the wish to establish a real partnership with 
participants and arguments against included the wish to protect the patient and to avoid 
generating anxiety or false hopes. 
 
Results of interviews 
Four researchers, 6 clinicians and 5 co-ordinating physicians were interviewed. All of 
them agreed that the global research results should be communicated to participants. However, 
the difficulty in explaining genetic results and the need to express scientific data in simple 
language were stressed by the physicians. It was suggested that global results should be 
communicated for the benefit of the participant, in the form of a letter or short note, with 
comments on the results obtained and details of the meetings and published articles in which the 
results had been presented. 
The communication of individual results was a source of disagreement between the 
three categories, although there was a consensus about the necessity to plan and to anticipate 
this possibility. All the interviewees mentioned the need to train clinicians to deliver individual 
genetic results. They stressed the need for these results to be communicated by a physician, 
implying that he/her knows how to interpret the genetic data and can explain the significance of 
the results and their impact on clinical care. Several clinicians were convinced that the patients 
had agreed to provide samples on the assumption that they would receive individual feedback. 
Some suggested that the decision to communicate results should be made on a case-by-case 
basis and pointed out the difficulty in making this decision before data are available. The 
professionals distinguished between two situations: 1) benefit to the participant, a situation that 
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clearly favours individual feedback, and 2) no recognised benefit, a situation that left the 
question open. It was pointed out that if the patient is informed that a particular genetic marker 
is associated with an increased medical risk, this patient is likely to ask about his or her own 
personal risk. It was also stressed that the participant should receive information about the 
relative level of risk, the notion of uncertainty, as well as the predictive rather than absolute 
nature of genetic determinism. Indeed, individual genetic results might be negative for the 
patient due to the uncertainty of how he/her will interpret his result in term of personal risk. The 
physicians responsible for co-ordinating the project raised the issue of individual feedback and 
the need to consider the participants in a personalised manner, adapted to their situation, when 
communicating results.  
Clinicians thought that using the term "benefit" was an important factor in encouraging 
patients to engage in the research protocol. One physician said that it might lead the participant 
to think that the research would have practical personal repercussions. For researchers, the term 
"benefit" could lead to confusion in the minds of participants concerning the chronology of the 
outcomes of research. They felt that it was the responsibility of the clinicians to explain the 
meaning of "benefit" and to differentiate between the benefit associated with participation in 
terms of follow-up and the benefit that might result solely from the data generated by the 
research. The physicians co-ordinating the project stated that the benefits could not be summed 
up simply in terms of consequences of the results on healthcare but that they also consisted of 
improvements in patient management through participation in the research itself, with regular 
general and psychological follow-up, involving standardised evaluation of the status of infection 
and complications. 
 
The participants' points of view 
The option concerning the communication of results in the consent form 
In 121 consent forms analysed, 54% of the participants indicated their wish to be 
informed of the results, even if they had no immediate impact on their treatment. Only half of 
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them provided their contact details or those of their physician. When personal contact details 
were provided, it was most frequently a telephone number, more rarely an address and 
exceptionally both. Among the 42 % of participants who did not indicate their choice, one fifth 
gave personal contact details. Only 4% clearly rejected the option of being informed of the 
results and did not leave contact details. 
 
The expectations of participants in terms of result feedback 
Twenty-two centres agreed to distribute the questionnaire, which was returned by 125 
participants. In total, 76% wished to receive individual and 71% wished to receive collective 
results (table 1). Just 8% expressed no expectation of receiving any type of result. Less than one 
third said that they regularly read the annual information document (table 2). This was not due 
to distribution problems because only four participants commented that they were unaware of 
this document and regretted this. We found that 37% expected to receive results within one year 
and that 19% even expected results within six months (table 3). A high percentage of the 
participants (39%) did not know when results might be expected. When asked about the 
possible advantages and disadvantages of having access to personalised genetic information, 
76% cited the possibility of adapting the treatment to the person, 72% cited the possibility of 
knowing about the progression of the disease and 39% foresaw opportunities for prevention 
(table 4). Only 7% had no opinions on this issue. The disadvantages were rarely mentioned, 
with intrusion into private life being cited in 5% of cases: no other disadvantages were 
mentioned. When questioned about their motivations for participating in research (table 5), a 
high percentage (85%) answered that they hoped for discoveries that would be useful to all 
patients. The hope of discoveries useful for themselves was the next most frequent response 
(67%). They also cited the possibility of better follow-up (30%) and greater involvement in the 
management of their own disease (24%). The minimal nature of the constraints imposed was 
cited in 16% of cases. The motive for participation was rarely a desire to please the physician 
and never due to a passive attitude linked to a difficulty in refusing. One patient cited 
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"recognition of the medical assistance I am receiving."
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DISCUSSION 
 
Whether results should be given to research participants is a complex question that is 
encountered in research in general and in research for genetic markers more particularly11,12,27,28. 
There is an international consensus that overall results should be communicated to patients after 
publication and after being peer-reviewed by the scientific community7,29. However, studies 
show that only a small number of clinical trials are actually published 10,16,17. In France, a law 
concerning patients' rights30 made the transmission of global results to research participants 
mandatory in 2002.  
In our study, the members of the APROCO cohort who agreed to participate in this 
pharmacogenetics study clearly expressed the wish to have access to both global and individual 
research results, even if they had no impact on their medical care. This reflects the need for 
feedback as an acknowledgement of their contribution to the research that may help them to 
better understand their disease. It probably also explains our results showing that patients take 
part in research for altruistic reasons, while hoping at the same time for personal benefits.  
Most professionals involved in the APROCO research are in favour of informing participants of 
the global results. Feedback may be viewed differently according to the study population and 
the severity of the disease when research may generate new care and treatment options. This is 
particularly true for HIV-infected patients and for protocols that are presented as having 
potential benefits. It is difficult to predict individual behaviours even when faced with global 
results; some individuals will be tempted to identify their own results, and the uncertainty 
associated with these data might trigger anxiety. Genetic and HIV provided a combination 
which favoured the emergence of demand for access to research results and the interaction 
between patients and the scientific community.  
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Our work underlines the importance of adapting the major ethical principles applied in clinical 
research31  to the specific issues raised by pharmacogenetics5,6. Indeed, these principles should 
evolve with time. To fulfil the ethical issue of transparency with respect to information and 
consent, the initial information should be completed, if necessary, to take into account research 
developments, its outcomes and results. Out of loyalty to the patient, if the study changes 
considerably or new genes are studied, asking for a new consent should be considered. 
Furthermore, as in any other protocol, but in a more sensitive manner (due to the representation 
of genetic, its impact on the future well-being of the individual and his family), the respect for 
confidentiality and privacy is required as well as the necessity to educate the patient on the 
nature of pharmacogenetics data in term of medical impact5,6. This would allow the patients to 
decide to participate in the protocol in a truly informed way, knowing about the risk-benefit 
ration, and to allow them to withdraw from the study at any time as a consequence of 
information given to them.  The right not to know as well as the participants changing their 
mind, particularly in long-term studies, need to be considered. During the delivering of 
information and consent, this needs to be integrated from the start within the doctor-patient 
relationship. This is particularly important when dealing with data that are significant for the 
participants’ health as added to the Helsinki declaration in Tokyo in 2004 on ethical principles 
for medical research involving human subjects31 and emphasise the need for research ethics 
committees to evolve in the accompanying of research protocols and cohorts. 
 
Ethical issues of the initial information given to the participants: the uncertainty of benefit 
To avoid false hopes, our results show that the term ‘benefit’ used on consent forms should be 
defined more accurately at the time of initial consent. It is advisable to differentiate a potential 
benefit associated with closer medical follow-up, which is inherent to the methodological 
requirements of the research, from the possible benefit associated with the results i.e. the early 
detection of complications and the intrinsic efficacy of treatment. The latter is uncertain and 
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remains subjective both scientifically and in terms of application delay. We think that it would 
be better to talk about "possible benefit" and to avoid the term "direct individual benefit" as 
previously recommended by the French law concerning biomedical research until 200432. Our 
results are compatible with the new formulation of the law proposed in 2004 in which the term 
"expected benefit" is preferred33. This term conveys the idea of incertitude about benefit. This is 
even more relevant given that this notion can change over time and depending on the research 
protocol. The questions raised in pharmacogenetics are sensitive because of the highly symbolic 
representation of genetics dealing with the individual privacy together with a familial 
dimension. There is also the uncertain nature of the individual benefit to the participant 
depending on the gene studied. 
Furthermore, concerning the potential benefit issued from the research results, our study 
highlights three cases: 1) the benefit to the participant is obvious and the communication of 
results would not generate anxiety. The result might then be given to the participant; 2) the 
result might be useful for the patient’s care but is associated with a poor prognosis and is 
predictive of an increased risk of morbidity or mortality. The principle of duty to inform34,35 
should then be applied even though this is delicate 3) the result has no demonstrated impact for 
care. Feedback should then be considered only if the participant has expressed the wish to be 
informed of the results in the conditions proposed in the research protocol. In all cases, the 
participant's decision not to be informed should be taken into account remembering that his/her 
point of view can differ from that expressed initially. In addition, the most appropriate 
communication strategy needs to be defined. These situations show that, even if it is logical to 
tend towards giving research participants as much information as possible, it is not clear that 
this is beneficial for the patients. In APROCO, each patient was asked to state in the informed 
consent form whether he or she wished to be informed of the results 12. This formulation does 
not distinguish between beneficial results and results associated with a poor prognosis. The 
APROCO research group currently thinks that the consent form needs to be revised so that it no 
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longer asks participants whether they wish to receive their results, but instead informs them that 
the results will be transmitted via their clinical physician if they could have a recognised and 
validated clinical impact. This would allow doctors to explain the results and to modify them 
according to the patient's clinical situation and psychological state, as is the case with all 
medical test results. Thus, our work shows that results should be returned to participants as part 
of the doctor-patient relationship. So, results could be modulated by clinicians as outlined in the 
French Code of Deontology, which states that a patient's condition can temporarily be kept 
secret for his own protection36. 
 
Importance of continuously providing information  
Our results highlight the importance of providing information regularly and 
continuously, to keep the participants updated of how research is progressing over time, to 
inform them about the choice of new markers and to discuss the expected benefits. Furthermore, 
the importance of delivering information continuously is to take into account the gap between 
the time in which the participants expect research results and the real time taken to obtain them.  
 This approach, which meets the demands of patients’ associations, has been adopted in 
the APROCO cohort where information is provided through consultations and through a 
bulletin written for patients. Establishing a partnership between participants and researchers 
improves compliance with protocols. Furthermore, this attitude is necessary to ensure that the 
consent obtained upon inclusion remains informed and valid over time when scientific choices 
change.  
 
Transfer of research results to clinical situations  
These questions highlight the therapeutic orientation of clinical research37 and the conditions for 
the use of pharmacogenetic research results in a clinical approach. Five essential conditions are 
recognised for the communication of individual results29,38: the desire of the person giving the 
sample to know, the scientific validation and confirmation of the results, the results having a 
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significant implication for the health of individuals, the existence of means of prevention or 
treatment and the possibility of a consultation with a professional expert in the domain. 
Accordingly, it will be essential to determine who will evaluate the medical impact and how. As 
is the case in this study, a multidisciplinary steering committee (ethics experts, lawyers and 
representatives of patients' associations) could meet to identify the most significant results, to 
plan their validation, to decide whether to diffuse them individually and to organise the 
transition towards individual feedback. It is essential to separate the returning of global results 
from individual results. The time taken to validate the procedures for the transition from global 
to individual results should also be used to educate the participants about the consequences of 
having access to individual results. They need to be told about the impact on their healthcare 
and about the risks of undue pressure from employers, insurers, or both that my not be in their 
interest (benefit-risk ratio). This question relates to a fundamental ethical rule that, as for any 
other medical data, research data should not be communicated to third parties39. 
Once the choice to communicate results has been taken, it is necessary to revalidate the data in a 
non-anonymous fashion by accredited laboratories, which requires considerable financial and 
logistic organisation. This would involve ensuring the traceability of participants so that they 
can be contacted and the development of pedagogical tools adapted to clinical situations, as 
described for cancer patients40. The results of research in pharmacogenetics could be discussed 
during consultations, making it possible to place these results concerning polymorphisms 
(different from the situation for single-gene diseases) within the context of other clinical and 
biological results, thereby illustrating their relative impact on the overall management of the 
disease. Furthermore, the possibility of giving participants priority access to the therapeutic 
benefits of research should be considered.  
In conclusion, in accordance with current discussions about the communication of 
results in clinical research, our work applied to pharmacogenetics in the field of HIV infection 
highlights the need to integrate into research protocols the ethical stakes relating to information 
procedures.  
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TABLE 
Answers of 125 HIV infected treated participants in the APROCO cohort to 4 questions 
dealing with research results. 
 
Question 1: Do you expect to receive information about the results?  
For the whole group? Related specifically to yourself? 
 
% 
Global and individual 59.2
Individual only 17.6
Global only 12 
None 8 
Don't know 3.2 
Question 2 : Do you read the annual document of information at the intention 
 of the research participants and addressed by the physician? 
 
% 
Yes, occasionally 40.8
No, never 36 
Yes, regularly 17.6
No reply 5.6 
Question 3 : When do you think that the results for the genetic research 
protocol will be available? 
 
% 
Less than 6 months 19.2
6 months to 1 year 18.4
1 to several years 19.2
Don't know 43.2
Question 4: What, in your opinion, are the advantages and disadvantages 
 of having access to personalised genetic information? 
(Several responses possible) 
 
% 
Treatment adapted to my personal needs 76 
Possibility of prevention 39.2
Understanding of disease progression 72 
Intrusion in private life 4.8 
Don't know 7.2 
Other, specify 0 
  
 
 
 
 
